AllergyTalk

For today’s episode we will be reviewing articles from the May-June 2021 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.

Articles Reviewed:

AZT Improves Outcomes and Lowers Costs in Uncontrolled Asthma

The cost-effectiveness of azithromycin in reducing exacerbations in uncontrolled asthma.

Cefazolin Should Be Used in Most Penicillin Allergic Patients

Assessment of the Frequency of Dual Allergy to Penicillins and Cefazolin: A Systematic Review and Meta-analysis.

Consider IV Fluids Early if Anaphylaxis Doesn’t Respond to Epinephrine

Cardiovascular changes during peanut-induced allergic reactions in human subjects.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: [email protected]

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

At the time of recording, the speakers had the following disclosures:

Dr. Lee has nothing to disclose

Dr. Kalangara Speaker and Consultant: GlaxoSmithKline

Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue!

Today we are again joined by Dr. Vivian Hernandez-Trujillo from Nicklaus Children’s Hospital and will be reviewing the July-Aug 2022 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. 

You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

Articles Reviewed:

Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations.

Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis.

Importance of Supplemental Patch Testing Beyond a Screening Series for Patients With Dermatitis: The North American Contact Dermatitis Group Experience.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: [email protected]

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Lee has nothing to disclose

Dr. Hernandez-Trujillo: 

Speaker Takeda, CSL

Advisory boards Takeda, Regeneron, Sanofi

Consultant  Kaleo, Pharming, Enzyvant, National Peanut Board, Allergy and Asthma Network

Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue!

Today we are again joined by Dr. Anthony Montanaro from Oregon Health & Science University and will be reviewing the Jan-Feb 2022 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. 

You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

Articles Reviewed:

Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations.

Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis.

Importance of Supplemental Patch Testing Beyond a Screening Series for Patients With Dermatitis: The North American Contact Dermatitis Group Experience.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: [email protected]

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Lee has nothing to disclose

Dr. Montanaro has done research with AstraZeneca, Regeneron, Theravance, and Teva

Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst, Novartis

Welcome to Season Two of Allergytalk! Starting with this episode, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue!

Today we are joined by Dr. Anthony Montanaro from Oregon Health & Science University and will be reviewing the Jan-Feb 2022 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. 

You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

Articles Reviewed:

Use of multiple epinephrine doses in anaphylaxis: A systematic review and meta-analysis.

First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing.

Differences in oral food challenge reaction severity based on increasing age in a pediatric population.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: [email protected]

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Episode 3: Severe pediatric asthma-beyond standard therapy, the role of current and future therapies including biologics

Description: Though severe pediatric asthma only represents from 2 to 5% of the children suffering with this condition, it represents a major share of the cost, resource utilization, and morbidity. It is important that allergists have a good gasp of this condition and how it differs from the adult population. Topics include appropriate workup, comorbidities, steroid burden.  

Learning Objectives:

1. Be able to discuss the burden of severe pediatric asthma and issues in optimal medication adherence in this population

References:              

1. Perry, R., Braileanu, G., Palmer, T. et al. The Economic Burden of Pediatric Asthma in the United States: Literature Review of Current Evidence. PharmacoEconomics 37, 155–167 (2019).

Episode 2:       Severe pediatric asthma-evaluation of the child, diagnostic testing, assessing steroid side effects

Description: Though severe pediatric asthma only represents from 2 to 5% of the children suffering with this condition, it represents a major share of the cost, resource utilization, and morbidity. It is important that allergists have a good gasp of this condition and how it differs from the adult population. Topics include appropriate workup, comorbidities, steroid burden.  

Learning Objectives:

1. Be able to discuss the burden of severe pediatric asthma and issues in optimal medication adherence in this population

References:              

1. Perry, R., Braileanu, G., Palmer, T. et al. The Economic Burden of Pediatric Asthma in the United States: Literature Review of Current Evidence. PharmacoEconomics 37, 155–167 (2019).

Episode 1: Severe pediatric asthma-burden of disease, adherence issues, and comorbidities

Description: Though severe pediatric asthma only represents from 2 to 5% of the children suffering with this condition, it represents a major share of the cost, resource utilization, and morbidity. It is important that allergists have a good gasp of this condition and how it differs from the adult population. Topics include appropriate workup, comorbidities, steroid burden.  

Learning Objectives:

1. Be able to discuss the burden of severe pediatric asthma and issues in optimal medication adherence in this population

References:              

1. Perry, R., Braileanu, G., Palmer, T. et al. The Economic Burden of Pediatric Asthma in the United States: Literature Review of Current Evidence. PharmacoEconomics 37, 155–167 (2019).

Episode 3 discusses access to treatment disparities for nasal polyposis in minority and underserved populations.

Today’s speakers have the following disclosures:

Gerald Lee, MD: Nothing to disclose

Maha Mahdavinia, MD, PhD: Consulting, Fee: Optinose

This podcast series is supported by Sanofi Regeneron.

Episode 2 discusses the impact of air pollution and the environment on CRSwNP and how this disproportionately affects minority and underserved populations.

Today’s speakers have the following disclosures:

Gerald Lee, MD: Nothing to disclose

Maha Mahdavinia, MD, PhD: Consulting, Fee: Optinose

This podcast series is supported by Sanofi Regeneron.

Episode 1 provides an overview of the subtypes of CRSwNP and reviews the evidence for disparities in the burden of disease on minority and underserved populations and discusses the reasons for these disparities.

Today’s speakers have the following disclosures:

Gerald Lee, MD: Nothing to disclose

Maha Mahdavinia, MD, PhD: Consulting, Fee: Optinose

Anjeni Keswani, MD: Nothing to disclose

This podcast series is supported by Sanofi Regeneron.